+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
N

Actively Recruiting

Immune thrombocytopenia ITP is a rare blood disorder caused by an autoimmune condition that reduces platelet counts, increasing the risk of bleeding or prolonged bleeding. New treatments for ITP have emerged recently, but existing clinical studies are limited in their applicability to everyday patient care due to strict criteria. This registry aims to collect real-world clinical data and biospecimens from patients with various types of ITP to improve understanding of diagnosis, therapy, and patient outcomes in routine treatment. The registry includes patients diagnosed with primary or secondary ITP who consent to participate. Data collection occurs at defined points in the disease course either prospectively or retrospectively up to 12 months after diagnosis, provided continuous documentation is available. Biospecimens are collected and stored systematically to support research. Clinical information collected includes disease characteristics, treatment types, complications, quality of life, fatigue scores, and survival data over a follow-up period of up to 5 years. Participants provide clinical data and biosamples at enrollment, then again at 6 months and annually for up to 5 years. Assessments include platelet counts, bleeding and thromboembolic events, laboratory markers such as specific antibodies, and patient-reported outcomes like quality of life and fatigue. The study gathers epidemiological data on incidence, age, sex distribution, causes of ITP, treatment received, and remission status. The registry helps advance knowledge about ITP through long-term monitoring and standardized data collection.

Age: 18Years +All Genders
64 locations
P

Actively Recruiting

Cholangiocarcinoma is a rare and aggressive bile duct tumor with limited treatment options and a poor prognosis. Researchers are collecting real-world data on the use of the targeted drug ivosidenib in adults with locally advanced or metastatic cholangiocarcinoma who have an IDH1 R132 mutation and have already received at least one prior systemic therapy. This prospective, multicenter observational study in Germany aims to provide evidence on the effectiveness, quality of life, and safety of ivosidenib in a broad patient population. Ivosidenib will be given following the current summary of product characteristics SmPC. The study will observe patients treated with ivosidenib in routine clinical practice without altering their treatment. Data will be gathered over a maximum period of 38 months from first patient inclusion to last patient last visit, covering treatment duration and patient outcomes during this time. Participants will be monitored regularly to assess progression-free survival as the primary outcome, along with overall survival, response rates, adverse events, and quality of life measures related to cholangiocarcinoma. The study also collects information on dose modifications, treatment duration, previous therapies, concomitant medications, and physician treatment decisions. This observational study continues until December 2027, allowing long-term follow-up of patients receiving ivosidenib.

Age: 18Years +All Genders
19 locations
C

Actively Recruiting

Researchers are evaluating two treatment optionssurgery and rigid collar bracingfor unstable odontoid neck fractures in adults aged 70 years and older. These fractures are common in older adults and can affect mobility, independence, and quality of life. The study aims to determine which treatment leads to better recovery in daily living, pain, disability, and quality of life. This is a randomized controlled trial comparing surgical stabilization with conservative collar treatment for this population. Participants will be randomly assigned to either surgery involving posterior C1-C2 screw-rod fixation or conservative treatment using a rigid cervical collar for 12 weeks. Surgery typically lasts about 100 minutes with a hospital stay of approximately six days, while the collar group is monitored through patient diaries to track compliance. Those in the collar group may switch to surgery within 12 weeks if needed. Follow-up visits occur at about two weeks post-surgery, 12 weeks, and six months after treatment. During the study, participants will complete questionnaires assessing daily function, pain, and quality of life. CT scans and other medical assessments will be performed, and collar use will be recorded for those in the conservative group. Researchers will monitor treatment adherence, complications, crossover rates, and healing progress. The main outcome measured is the change in the Barthel Index for daily living activities at 12 weeks, with additional evaluations at six months. The total study duration includes follow-up visits up to six months after injury.

Age: 70Years +All GendersPhase Not Applicable
16 locations
O

Actively Recruiting

Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines. Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies. During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.

Age: 18Years +All Genders
74 locations